Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of PRV111 in Subjects With Oral Squamous Cell Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Pathologically confirmed T1 (\<2 cm) or T2 (\>2 cm but \< or = 4 cm) squamous cell carcinoma (SCC) of the lip or oral cavity (anterior 2/3 of the tongue, floor of mouth, lower and upper gingiva, salivary gland, hard palate, and buccal mucosa).~2. Tumor must be easily accessible, with no evidence of infection or active bleeding, encroaching major vessels or clinical evidence of neural invasion. Not previously irradiated.~3. Tumors must be amenable to surgical resection no later than 21 days post Visit 1.~4. Clinically or radiologically measurable tumor.~5. ECOG Performance Status of \< or =2.~6. Adequate renal function as demonstrated by renal creatinine clearance.~7. Adequate organ function as assessed by safety labs.~8. Agree to use effective contraception for 30 days after the last dose of study drug.~9. Absence of any serious medical conditions that would impair the subject's ability to participate.~10. Willing and able to provide written informed consent.~11. Able to return to the study site for treatment and follow-up visits as defined in the protocol.~Exclusion Criteria:~1. Known distal metastasis of the SCC of the oral cavity.~2. Systemic chemotherapy for the treatment of SCC of the head and neck less than 2 years prior to screening.~3. Concurrent documented malignancy, with the exception of localized SCC of the skin.~4. Exposure to any investigational agent within 3 months prior to screening.~5. Known allergy or hypersensitivity to platinum-containing agents.~6. Active, uncontrolled infection requiring systemic therapy.~7. Known or suspected pregnancy, planned pregnancy or lactation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open-Label, Single Arm Study of PRV111 (Type: EXPERIMENTAL): Subjects received 3 treatment applications of PRV111 (Cisplatin Transmucosal System) at each of the 4 planned visits within 3 weeks prior to their tumor surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).